Write in a clean editor, then format for Current Research in Pharmacology and Drug Discovery in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Current Research in Pharmacology and Drug Discovery is a peer-reviewed journal published by Elsevier, covering Computational Drug Discovery Methods, Diverse Scientific and Economic Studies, COVID-19 Clinical Research Studies.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Current Research in Pharmacology and Drug Discovery 12 (2023) 45–58.
Formats any DOI in Current Research in Pharmacology and Drug Discovery style. No sign-up. |
| Publishes research in | Computational Drug Discovery Methods Diverse Scientific and Economic Studies COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Inflammatory Bowel Disease |
| ISSN | 2590-2571 |
| Citation impact (2-yr) | 5.62 |
| h-index | 34 |
| i10-index | 112 |
| Total citations | 4,105 |
| Article processing charge | $2,500 |
| Open access | Yes |
| Top institutions publishing here | University of Parma |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Current cancer therapy includes a variety of strategies that can comprise only one type of treatment or a combination of multiple treatments. Chemotherapy is still the gold standard for cancer therapy, though sometimes associated with undesired side effects and the development of drug resistance. For this reason, drug combination is an approach that has been…
Cancer continues to increase global morbidity and mortality rates. Despite substantial progress in the development of various chemically synthesized anti-cancer drugs, the poor prognosis of the disease still remains a big challenge. The most common drawback of conventional cancer therapies is the emergence of drug resistance eventually leading to the discontinuation of chemotherapy. Moreover, advanced…
The DNA damage response (DDR) is now known to play an important role in both cancer development and its treatment. Targeting proteins such as ATR (Ataxia telangiectasia mutated and Rad3-related) kinase, a major regulator of DDR, has demonstrated significant therapeutic potential in cancer treatment, with ATR inhibitors having shown anti-tumour activity not just as monotherapies,…
Neurodegeneration and synaptic loss in Alzheimer's disease (AD) lead to impairment in memory functions. Neuroinflammation causes activation of microglia and astrocytes cells that locally and systemically produces inflammatory cytokines which can serve as early diagnostic markers or therapeutic targets in AD. Pro-inflammatory cytokines (Interleukins (IL-1β, IL-6 and IL-10) and tumor necrosis factor (TNF α)) levels…
The coronavirus disease 2019 (COVID-19) pandemic has undoubtedly become a global crisis. Consequently, discovery and identification of new or known potential drug candidates to solve the health problems caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become an urgent necessity. This current research study sheds light on the possible direct repurposing of…
